Danish Hypertension Prevention Project - DHYPP

• Status: Unknown status
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The present study examine healthy, normotensive subjects 18 to 36 years of age whose both parents have essential hypertension. The subjects receive treatment with either the AT1-antagonist candesartan cilexetil, 16 mg daily or placebo for one year. Then, treatment is withdrawn and the subjects is followed for 10 years to determine if the treatment has been able to either prevent or delay the development of hypertension. The primary objective is to determine whether pharmacological treatment with an angiotensin receptor blocker is able to restrain or delay the progression to hypertension. Secondary objectives are to investigate whether any long-term effect on blood pressure is related to the effect of treatment on renal haemodynamic function, or on the left ventricle mass.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Karin Skov
• Collaborators: AstraZeneca; University of Aarhus
• Treatments: Candesartan; Candesartan cilexetil

Criteria

Inclusion Criteria:

1. Both parents have essential hypertension

2. Age 18 - 36 years

3. Caucasians

4. Diastolic blood pressure less than 85 mmHg at inclusion time

5. Female participants using orale anticonceptives ot intrauterine devices

Exclusion Criteria:

1. Clinical or biochemically signs of disease in kidney, liver, or endocrine organs

2. Diastolic blood pressure above 85 mmHg at inclusion time

3. Pregnancy or pregnancy wish

4. Daily medication, except for orale anticoncetives -